D. Klatzmann, P. Ché-rin, and G. Bensimon, A Phase I/II Dose-Escalation Study of Herpes Simplex Virus Type 1 Thymidine Kinase ???Suicide??? Gene Therapy for Metastatic Melanoma, Human Gene Therapy, vol.9, issue.17, pp.2585-2594, 1998.
DOI : 10.1089/hum.1998.9.17-2585

D. Klatzmann, C. Valé-ry, and G. Bensimon, A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase ???Suicide??? Gene Therapy for Recurrent Glioblastoma, Human Gene Therapy, vol.9, issue.17, pp.2595-2604, 1998.
DOI : 10.1089/hum.1998.9.17-2595

C. Valé-ry, D. Seilhean, and O. Boyer, Long-term survival after gene therapy for a recurrent glioblastoma, Neurology, vol.58, issue.7, pp.1109-1112, 2002.
DOI : 10.1212/WNL.58.7.1109

C. Dalba, D. Klatzmann, and C. Logg, Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors, Current Gene Therapy, vol.5, issue.6, pp.655-667, 2005.
DOI : 10.2174/156652305774964659

C. Dalba, B. Bellier, and N. Kasahara, Replication-competent Vectors and Empty Virus-like Particles: New Retroviral Vector Designs for Cancer Gene Therapy or Vaccines, Molecular Therapy, vol.15, issue.3, pp.457-466, 2007.
DOI : 10.1038/sj.mt.6300054

W. Wang, C. Tai, and N. Kasahara, Highly Efficient and Tumor-Restricted Gene Transfer to Malignant Gliomas by Replication-Competent Retroviral Vectors, Human Gene Therapy, vol.14, issue.2, pp.117-127, 2003.
DOI : 10.1089/104303403321070810

S. Solly, S. Trajcevski, and C. Frisé-n, Replicative retroviral vectors for cancer gene therapy, Cancer Gene Therapy, vol.10, issue.1, pp.30-39, 2003.
DOI : 10.1016/S0958-1669(99)00009-9
URL : http://www.nature.com/cgt/journal/v10/n1/pdf/7700521a.pdf

S. Trajcevski, S. Solly, and C. Frisé-n, Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors, The Journal of Gene Medicine, vol.11, issue.3, pp.276-287, 2005.
DOI : 10.1038/sj.gt.3302138

T. Cloughesy, J. Landolfi, and D. Hogan, Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma, Science Translational Medicine, vol.8, issue.341, pp.341-75, 2016.
DOI : 10.1126/science.1155390

T. Huang, S. Parab, and R. Burnett, Intravenous Administration of Retroviral Replicating Vector, Toca 511, Demonstrates Therapeutic Efficacy in Orthotopic Immune-Competent Mouse Glioma Model, Human Gene Therapy, vol.26, issue.2, pp.82-93, 2015.
DOI : 10.1089/hum.2014.100

D. Saadoun, M. Rosenzwajg, and F. Joly, Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis, New England Journal of Medicine, vol.365, issue.22, pp.2067-2077, 2011.
DOI : 10.1056/NEJMoa1105143

D. Klatzmann and A. Abbas, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases, Nature Reviews Immunology, vol.134, issue.5, pp.283-294, 2015.
DOI : 10.1016/S0140-6736(00)02799-9
URL : https://hal.archives-ouvertes.fr/inserm-01617541

G. Churlaud, V. Jimenez, and J. Ruberte, Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer, Clinical Immunology, vol.151, issue.2, pp.114-126, 2014.
DOI : 10.1016/j.clim.2014.02.003

S. Alves, G. Churlaud, and M. Audrain, Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer???s disease mice, Brain, vol.140, pp.826-842, 2017.
DOI : 10.1093/brain/aww330
URL : https://hal.archives-ouvertes.fr/hal-01430973